<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387530</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-050126</org_study_id>
    <secondary_id>CDR0000504022</secondary_id>
    <secondary_id>ROCHE-VAL-108</secondary_id>
    <nct_id>NCT00387530</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer</brief_title>
  <official_title>A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders.&#xD;
      Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate&#xD;
      may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving&#xD;
      phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr&#xD;
      virus-infected cells and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with&#xD;
      valganciclovir works in treating patients with relapsed or refractory Epstein-Barr&#xD;
      virus-positive cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the rate of Epstein-Barr virus (EBV) lytic phase activation by BZLF1&#xD;
           expression in patients with relapsed or refractory, EBV-positive malignancies treated&#xD;
           with phenylbutyrate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine tumor responses in patients treated with phenylbutyrate followed by&#xD;
           valganciclovir.&#xD;
&#xD;
        -  Track serum EBV load by quantitative polymerase chain reaction and correlate changes&#xD;
           with EBV lytic phase activation/tumor response.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive oral phenylbutyrate three times daily on days 1-21 and oral valganciclovir&#xD;
      once or twice daily on days 4-21. Treatment repeats every 21 days for up to 2 years in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo biopsy on day 3 of course 1. Serum Epstein-Barr virus DNA is analyzed for&#xD;
      expression of BZLF1 and LMP2 by quantitative polymerase chain reaction on days 3 and 14 of&#xD;
      course 1 and on day 1 of each subsequent course.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 and 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">May 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of Epstein-Barr virus (EBV) lytic phase activation (expression of EBV antigens BZLF1 and LMP2) as assessed by biopsy on day 3 of course 1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response in patients with measurable disease as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <arm_group>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral sodium phenylbutyrate</intervention_name>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>Single Arm Study of Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-proven Epstein-Barr virus (EBV)-positive malignancy&#xD;
&#xD;
               -  Must have tissue analysis to confirm EBV positivity&#xD;
&#xD;
                    -  Archival tissue ≤ 1 year old may be used&#xD;
&#xD;
          -  Any of the following malignancies:&#xD;
&#xD;
               -  WHO type II or III nasopharyngeal carcinoma&#xD;
&#xD;
               -  Post-transplant lymphoproliferative disorder&#xD;
&#xD;
               -  Nasal NK/T-cell lymphoma&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
               -  Lymphoepithelioma-variant gastric carcinoma&#xD;
&#xD;
               -  AIDS-related lymphomas&#xD;
&#xD;
                    -  Patients with CNS non-Hodgkin's lymphoma must have tumor cells present in&#xD;
                       the cerebrospinal fluid (and assessable with lumbar puncture)&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
               -  Must have received and failed all prior potentially curative treatment for&#xD;
                  disease&#xD;
&#xD;
               -  Eligible only for salvage therapy&#xD;
&#xD;
          -  Must have tumor tissue amenable for minimally invasive biopsy (e.g., fine-needle&#xD;
             aspiration or bone marrow biopsy)&#xD;
&#xD;
               -  No brain tumors not amenable to biopsy&#xD;
&#xD;
          -  CNS metastases allowed provided ≥ 2 weeks since prior radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Recovered from uncontrolled intercurrent illness, including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
          -  Able to take medication orally or by gastrostomy tube&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to, during, and for 90 days&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No uncontrolled grade 1 symptomatic diarrhea (i.e., &gt; 3 stools/day)&#xD;
&#xD;
          -  No concurrent serious medical or psychiatric illness that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent cerebrospinal fluid drugs allowed&#xD;
&#xD;
          -  No concurrent zidovudine for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L. Read, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

